Relay Therapeutics, Inc. cash flow to debt ratio of -725.41% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Relay Therapeutics, Inc.'s free cash flow has increased -6.08% from $-251.12M last year to $-235.87M, signaling increasing performance

Relay Therapeutics, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Relay Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.06 last year to 0.05 today, signaling strengthened financials

Relay Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Relay Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Relay Therapeutics, Inc.'s profit margin has increased (-24.32%) in the last year from -3.37K% to -2.55K%, signaling increasing performance

Relay Therapeutics, Inc.'s short-term assets of $578.28M exceed its short-term liabilities of $25.58M

Relay Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Relay Therapeutics, Inc.'s return on equity of -43.94%, is lower than 15.00%, indicating bad performance

Relay Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Relay Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Relay Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Relay Therapeutics, Inc. has negative free cash flow, indicating cash burn

Relay Therapeutics, Inc.'s yearly earnings has increased -18.13% since last year from $-337.71M to $-276.48M, signaling increasing performance

Relay Therapeutics, Inc.'s yearly revenue has increased 53.44% since last year from $10.01M to $15.36M, signaling increasing performance

ROIC -44.00% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Relay Therapeutics, Inc.'s 3-year revenue CAGR of 123.20% is positive, indicating growing revenue over the past 3 years

Relay Therapeutics, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Relay Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Relay Therapeutics, Inc. has insufficient data to evaluate this check.

Relay Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Relay Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Relay Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Relay Therapeutics, Inc. has insufficient data to evaluate this check.

Relay Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Relay Therapeutics, Inc. has a price-to-book ratio of 5.20x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Relay Therapeutics, Inc. has a price-to-sales ratio of 304.23x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue